Market News

Global Urinary Tract Infection Therapeutic Market: Key Developments

On January 23, 2024, Locus Biosciences, Inc., a clinical-stage biotechnology company, announced the release of USD 23.9 million from the Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to continue the development of Locus Biosciences, Inc.'s Clustered regularly interspaced short palindromic repeats (CRISPR)-enhanced bacteriophage therapy, LBP-EC01, for treating urinary tract infections (UTIs) caused by drug-resistant Escherichia coli.

In April 2023, GSK plc, a multinational pharmaceutical and biotechnology company, reported positive results from the pivotal EAGLE-2 and EAGLE-3 phase III trials of gepotidacin, an investigational, first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urinary tract infections (uUTI) in female adults and adolescents. The findings were presented in an oral presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Copenhagen, Denmark.

In August 2021, Bayer AG, a Germany-based multinational pharmaceutical and biotechnology company, announced the acquisition of Vividion Therapeutics (Vividion), a U.S.-headquartered biopharmaceutical company using novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics.

In October 2020, Bayer AG, acquired Asklepios BioPharmaceutical, Inc., a gene therapy company. Asklepios BioPharmaceutical, Inc.`s portfolio includes investigational pre-clinical and clinical stage candidates for the treatment of central nervous system, neuromuscular, and cardiovascular and metabolic diseases.

In January 2019, AstraZeneca, a global, science-led biopharmaceutical business, completed the acquisition of Shire, a biopharmaceutical company, bringing together Takeda Pharmaceutical Company Limited, a global biopharmaceutical company and Shire's complementary positions in gastrointestinal and neuroscience to establish leading positions in rare diseases complement Takeda's previously existing strength in oncology and focused efforts in vaccines.